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ABSTRACT Many patients with idiopathic pulmonary fibrosis (IPF) complain of chronic refractory
cough. Chronic cough is a distressing and disabling symptom with a major impact on quality of life.
During recent years, progress has been made in gaining insight into the pathogenesis of cough in IPF,
which is most probably “multifactorial” and influenced by mechanical, biochemical and neurosensory
changes, with an important role for comorbidities as well. Clinical trials of cough treatment in IPF are
emerging, and cough is increasingly included as a secondary end-point in trials assessing new compounds
for IPF. It is important that such studies include adequate end-points to assess cough both objectively and
subjectively. This article summarises the latest insights into chronic cough in IPF. It describes the different
theories regarding the pathophysiology of cough, reviews the different methods to assess cough and deals
with recent and future developments in the treatment of cough in IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown cause with a median survival
of 3–5 years after diagnosis [1]. Treatment of IPF aims at slowing or stopping the disease progression,
increasing survival, reducing symptoms and improving quality of life (QoL) [2]. Currently, two
anti-fibrotic drugs are available that slow down disease progression [3, 4]. In a small minority of patients
lung transplantation is an option that can increase survival and improve QoL. Alleviating symptoms and
improving QoL in IPF is often a major challenge to treating clinicians. Patients report that the symptoms
that have the greatest impact on daily life are cough, shortness of breath and fatigue or malaise [2].
Chronic cough in IPF is not only often refractory, but is also an independent predictor of disease
progression [5]. Better understanding of the underlying mechanism(s) causing cough in IPF and better
treatments are clearly needed. This review summarises the latest insights on chronic cough in IPF.
Characteristics and demographics of chronic cough
Chronic cough is defined as a cough lasting for at least 8 weeks. In the general population it has a
prevalence of 9% to 33% in the USA and Europe [6]. It is a frequent reason for seeking medical advice,
with a high number of medical consultations [7]. The most important risk factor for chronic cough is
cigarette smoking. Prevalence of chronic cough is three times higher in chronic smokers as in never- or
ex-smokers [6].
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COUGH IN IPF
No reliable data on the prevalence of cough in IPF exist. Some studies report that up to 80% of patients
experience chronic cough [5, 8]; however, lower numbers are also reported [4]. This may be attributed to
method of reporting and the definition of cough used (any cough versus disabling cough). When cough is
present in IPF, it is severe and difficult to treat [8]. The cough is mostly nonproductive and dry, although
some patients experience nonpurulent sputum production, possibly related to traction bronchiectasis in
advanced IPF or concomitant chronic obstructive pulmonary disease (COPD). The urge to cough cannot
be relieved by coughing [9].
Cough frequency is high in patients with IPF, with median (range) 24-h cough counts varying from 226
(36–946) to 520 (117–1493) depending on the population studied [10, 11]. The cough frequency in IPF is
similar to patients with chronic cough presenting to a cough specialist clinic, and higher than in patients
with asthma or COPD (asthma median (range) 24-h cough rate 62.4 (0–341), COPD ex-smokers 117.6
(range 14.4–648)) [10, 12]. Strikingly, IPF patients experience more cough symptoms during daytime
(median hourly cough rate 14.6 during the day versus 1.9 during the night), analogous with COPD and
asthma patients [10, 12]. Chronic cough in IPF is not related to age or gender, and is more common in
“advanced” disease and in never-smokers [5, 10], the latter is in contrast to chronic cough in the general
population [6]. There is no clear explanation why IPF patients without a history of smoking cough more,
but this may be related to the phenotype of IPF [13].
Effect on the patient
In general, chronic cough can impact severely on different aspects of life [14]. Problems with sleeping,
raucous vocal sounds and musculoskeletal pain of the chest can occur [9]. Chronic cough can cause
relationship difficulties, avoidance of public areas, decreased social interaction and work-related problems
affecting physical, mental and social health [14, 15]. In IPF, the limited studies about cough and QoL also
show that cough is a very disabling and distressing symptom impacting QoL [9, 10]. Some patients also
experience cough-related urinary incontinence with a dramatic impact on QoL [16]. Moreover, the social
impact of chronic cough in IPF further compounds limited exercise ability, reduced walking distance and
the need to use supplemental oxygen.
Pathophysiology of chronic cough
A detailed overview of the pathophysiology of cough is beyond the scope of this review; however, a
summary of the mechanisms that may play a role in cough in IPF [17] is shown in figure 1. Imbalance
between stimuli and responses results in increased coughing. Minor stimuli such as laughing, talking,
smoke, perfume and temperature changes already induce a cough reflex [6, 18]. This is also known as
cough hypersensitivity syndrome and can occur in patients with and without pulmonary disease [19].
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FIGURE 1 Pathophysiology of cough. TRPV1: transient receptor potential vanilloid 1; TRPA1: transient receptor
potential ankyrin 1; RAR: rapidly adapting receptor; SAR: slowly adapting receptor. Reproduced from [17] with
permission from the publisher.
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The cough reflex has an afferent pathway, with sensory nerve fibres of the vagus nerve located in the
ciliated epithelium of the upper airways and cardiac and oesophageal branches from the diaphragm [20].
These afferent impulses go to the brain stem and cortical centre, which are important in regulating the
cough response. In response this activates the efferent motor pathway of the cough reflex, by sending
impulses via the vagus, phrenic and spinal motor nerves to the diaphragm, abdominal wall and muscles,
resulting in cough [17, 18, 20].
The afferent part of the cough reflex involves at least three broad classes of nerves: C-fibres, rapidly
adapting receptors (RARs) and slowly adapting receptors (SARs) [20]. 1) C-fibres are sensitive to thermal
and chemical stimulation, such as capsaicin, citric acid and hypertonic saline. TRPV1 and TRPA1 are
C-fibre receptors that are very responsive to chemicals [20, 21]. 2) RARs are rapidly responsive to
mechanical stimulation, such as changes in, for example, diameter, length and compliance of the airways.
RARs are also sensitive to changes in PH and osmolality but relatively insensitive to other chemical
stimulation [22, 23]. 3) SARs are highly sensitive to mechanical forces and are thought to be the afferent
fibres involved in the Hering–Breuer reflex, which terminates inspiration and initiates expiration when the
lungs are adequately inflated [20].
Recently it has also been recognised that neuroplasticity, whereby nerves switch phenotype, can occur in
different disease processes [24]. Voluntary cough and the sensation of an urge to cough have their origin
in the cerebral cortex [18].
Pathophysiology of cough in IPF
The pathophysiology of chronic cough in IPF is still unknown and is complicated by the frequent
confounding comorbidities in this population. Different concepts of the possible mechanisms of cough in
IPF have been proposed [25].
There is some evidence that the cough reflex sensitivity in patients with IPF is increased [8, 26], suggesting
an upregulation of sensory fibres in the lungs [8, 26]. However, the studies assessing cough sensitivity were
performed before the publication of the current international guidelines for the diagnosis of IPF in 2011 [1].
Assuming that increased cough reflex sensitivity may play a role in at least part of the IPF population, the
question remains what causes this enhanced sensitivity.
A possible explanation could be that mechanical distortion of the lung, caused by the fibrosis, directly
influences nerve fibres. As RARs and SARs are sensitive to mechanical changes they could be influenced
in sensitivity or quantity by the traction forces of the fibrosis [22, 25]. Nerves that inhibit cough might
also be destroyed due to fibrosis [22]. This corresponds with the finding of increased cough reflex
sensitivity to mechanical stimulation of the chest wall in IPF patients, compared with controls. An
increased sensitivity was especially found following low frequency stimulation of the posterior basal lung
base, the area where lung fibrosis in IPF is typically most extensive [22]. This mechanism may also explain
the observation that cough seemed to be more frequent in advanced IPF, although in another study this
correlation was not found [5, 10]. Moreover, this is in line with clinical findings that patients often report
starting to cough when talking or not being able to stop coughing once they start. The transmission of
vibration caused by talking or even coughing itself might lead to increased mechanical stimulation of the
sensory receptors, perpetuating a cycle of more cough and more vibration [27].
Another explanation for enhanced cough sensitivity could be the higher levels of neurotrophins that have
been found in the sputum of patients with IPF than in controls [8, 25]. Neurotrophins induce the survival
and development of different subgroups of sensory neurones and can also cause increase capsaicin
sensitivity, enhancing cough reflex [8, 25, 26]. Immunohistochemical studies have shown that non-neuronal
cell types, such as bronchial and alveolar epithelial cells, mesenchymal cells, lymphocytes and macrophages,
can express neurotrophins [28]. In patients with idiopathic interstitial pneumonias, an increased expression
of neurotrophins in the lung was shown, suggesting that they may potentially modulate sensory nerve
proliferation and neuroplasticity [29]. Immunoblots revealed more neurotrophin expression in IPF/usual
interstitial pneumonia than in nonspecific interstitial pneumonia and respiratory bronchiolitis-associated
interstitial lung disease [29]. The underlying drivers of increased neurotrophin expression in IPF are
unknown, although in other diseases inflammation is related to increased neurotrophin expression [30].
Interestingly, cough is an independent predictor of disease progression and the amount of coughing is not
clearly related to the pulmonary function measurements [10]. LESLIE [31] suggested that recurrent stretch
injury caused by pressure changes during breathing may explain why fibrosis in IPF typically commences
in the peripheral basal part of the lung. LESLIE [31] argues that in these areas the traction forces and
alveolar collapse are greatest, leading to sheer stress, lung injury and activation of fibrotic cascades. By
analogy, mechanical ventilation in IPF can be a risk factor for acute exacerbations of the pulmonary
fibrosis [32]. If pressure differences play a role in the pathogenesis of IPF, it could be speculated that the
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pressure differences caused by cough might influence disease behaviour itself. One could hypothesise that
cough is not only a symptom, but may also contribute to enhance activation of profibrotic mechanisms
and disease worsening in IPF.
Furthermore, cough could be evoked centrally through cortical influences. The urge to cough, induced by
capsaicin inhalation, activates many areas of the cerebral cortex [33]. Administration of a placebo prior to
capsaicin testing can decrease activity in several brain regions [34]. This suggests that expectations of
treatment can influence central processing of peripheral sensory input [34]. Suppression of cough by
cortical influences could also explain why IPF patients cough less during their sleep.
Comorbidities influencing cough
In patients with IPF, a number of potential causes of chronic cough must be excluded before chronic cough
may be considered directly linked to the underlying disease. In at least half of patients comorbidities may
play a role (table 1) [35].
Gastro-oesophageal reflux disease (GORD) is highly prevalent in IPF, yet classical symptoms are often
absent [37, 38]. GORD-associated microaspiration of acid and non-acid reflux in the airway is thought to
induce epithelial damage and may cause fibrosis [45]. Traction caused by lung fibrosis also can result in a
weakened lower oesophageal sphincter, leading to gastro-oesophageal reflux and microaspiration [38, 46].
Cough receptors could be directly stimulated through aspiration of gastric secretions in the larynx and the
upper airways [6]. Moreover, the presence of acid in the distal oesophagus may induce cough, probably
through an oesophageal–tracheobronchial reflex [47]. Disappointingly, a study by KILDUFF et al. [48]
showed no improvement of cough by anti-acid treatments, but a paradoxical increase in non-acid reflux. It
might well be that non-acid reflux is influencing cough more than acidic reflux [48]. Unfortunately, cough
itself may also increase trans-diaphragmatic pressure and promote GORD [47].
Obstructive sleep apnoea (OSA) is common in IPF [39]. OSA itself, with intermittent hypoxaemia, may
promote profibrotic mechanisms [49]. In the general population, chronic cough is more prevalent in OSA
and can be improved by treatment with continuous positive airway pressure (CPAP) [50]. A complicating
factor is that obstruction of the upper airway in OSA could increase the trans-diaphragmatic pressure
difference promoting GORD [51, 52]. GORD, on the other hand, may promote OSA, through
microaspiration of gastric substances, creating an inflammatory reaction blocking the airway [53]. GORD,
chronic cough and, as recently shown, IPF can be improved by treatment of OSA [49, 51]. Figure 2 shows the
interplay between IPF, GORD, OSA and cough. Further research is needed to disentangle these interactions.
Additional comorbidities not directly linked to IPF should also be evaluated, especially cardiovascular
comorbidity and associated treatment. Left heart disease and the use of beta-blockers are possible causes of
chronic cough. Angiotensin converting enzyme (ACE) inhibitors as a cause of chronic cough should
always be checked. ACE inhibitors can cause enhanced cough receptor sensitivity leading to cough just
after taking the drugs, but also even months later. Symptoms can improve days after drug removal, but
can take longer to disappear completely [6]. In the work-up of cough in IPF, infections, chronic sinusitis,
COPD-associated chronic bronchitis and pulmonary malignancies should also be excluded.
Assessment of cough in IPF
In recent years, many tools have been developed to assess different aspects of cough; subjectively using cough
questionnaires or visual assessment scales, and objectively using cough recorders and cough challenge tests. All
these instruments have been developed for chronic cough in a general population and are reviewed elsewhere
[55]. Experience and validation of these tools in patients with IPF are limited (table 2 provides an overview).
TABLE 1 Comorbidities influencing cough in idiopathic pulmonary fibrosis (IPF)
Comorbidity Frequency in IPF (%) Reference(s)
GORD 21–94 [36–38]
OSA 59–88# [38–40]
Emphysema 30–55 [41]
ACE inhibitor use 9–15 [5, 42]
Chronic sinusitis/UACS 17–34 [5, 42, 43]
Lung cancer 4.4–16 [41, 44]
Infection 11–20 [3]
GORD: gastro-oesophageal reflux disease; OSA: obstructive sleep apnoea; ACE: angiotensin converting
enzyme; UACS: upper airway cough syndrome. #: with high mean body mass index of 28–32 kg·m−2.
DOI: 10.1183/16000617.0090-2015 281
COUGH IN IPF | M.J.G. VAN MANEN ET AL.
By analogy with chronic cough, we would recommend the visual analogue scale to measure the severity of
IPF related cough in a clinical setting, as it is fast and easy to use [60]. When designing a clinical trial,
validated subjective as well as objective cough outcome measures should be incorporated.
Treatment of cough in IPF
In clinical practice, cough in IPF is a major challenge for the treating physician and patient, as it is often
refractory. The first step in the management of chronic cough in IPF consists of addressing possible
comorbidities as described in table 1.
Conventional anti-tussive therapy is often not beneficial [8]. Oral corticosteroids have been shown to
improve cough symptoms in IPF patients in one small nonrandomised study [8], and low doses of
prednisone are sometimes tried in daily practice to relieve cough, and later are slowly tapered if beneficial.
However, no effect on QoL and survival was found and possible side-effects should be taken into
consideration. Although opiates are recommended in the palliative setting, their effect has not been proven
in IPF [1, 27]. Caution is warranted as opiates may influence the protective mechanism of cough, but
might be a useful option for palliation of severe cough in patients with advanced IPF. With respect to
GORD, no good evidence on the work-up and treatment of GORD-related cough in IPF exists, while the
effect of proton pump inhibitors on cough is debated [48, 61].
A 24 week single centre double-blind cross-over study with thalidomide for treatment of cough showed a
positive effect on QoL measured with the Cough Quality of Life Questionnaire. However, only 20% of the
screened subjects completed the study and the potential side-effects of thalidomide can be severe [43].
Thalidomide has anti-inflammatory and anti-angiogenic effects, similar to currently used anti-fibrotic
drugs. Its side-effect profile with dizziness and neuropathy suggests that it might also have effects on
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FIGURE 2 Interactions between idiopathic pulmonary fibrosis (IPF), gastro-oesophageal reflux disease (GORD),
obstructive sleep apnoea (OSA) and cough. 1: traction leading to a weaker lower oesophageal sphincter tonus [45];
2: microaspiration inducing epithelial damage [38, 46]; 3: restriction inducing instability of the upper airway [39];
4: intermitted hypoxaemia promoting profibrotic mechanisms [49]; 5: increased cough reflex sensitivity [22–31];
6: pressure causing stretch injury and activation of fibrotic mechanisms [31]; 7: microaspiration causing an
inflammatory reaction blocking the airway [53]; 8: obstruction increasing trans-diaphragmatic pressure [51, 52];
9: aspiration directly and acid reflux indirectly stimulate the cough reflex [6, 47]; 10: cough increasing
trans-diaphragmatic pressure [47]; 11: less central inhibition and inflammation increasing cough reflex
sensitivity [54].
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TABLE 2 Cough measurements in idiopathic pulmonary fibrosis (IPF) patients
Cough measurement tool Description Validation studies and MCID Advantages Disadvantages
Subjective
Visual analogue scale [56] 100 mm scale with extremes
no cough to worst possible
cough severity
Not validated in IPF Easy to use
Repeatable
Responsive
Not validated in IPF or chronic
cough
Cough quality-of-life
questionnaire [57]
28-item cough-specific
quality-of-life questionnaire
with six domains
Validated in IPF (n=23)
MCID in IPF: change of
five points on a 28–112
scale [57]
Comprehensive questionnaire
Reliable
Valid instrument for assessing
impact of cough
Need more studies in IPF:
MCID evaluated with a
retrospective anchor scale
Leicester cough
questionnaire [15]
19-item self-administered
chronic cough quality-of-life
questionnaire with three
domains
Evaluated in IPF: high
correlation found with
cough visual analogue
scale, cough symptom
score and objective cough
frequency in IPF [10, 22]
MCID in chronic cough: 1.3
High reliability
Valid instrument for assessing
impact of cough
Ability to detect a response
to change
Need more studies in IPF:
MCID evaluated in chronic
cough
Objective
Cough challenge test [58] Measurement of cough reflex
sensitivity by inhalation of
nebulised tussive agents
(most common citric acid or
capsaicin)
Not validated in IPF
No MCID
Standardised methodology
published by ERS [14]
Useful for testing effect of
new cough therapies on
cough reflex sensitivity and
for obtaining mechanistic
insights
Doesn’t measure efficacy of
therapy or predict response
in patients
Limited availability
Cough monitor [59] Microphone and recording
device measuring cough in
a pre-specified time slot
Validated cough monitors for
chronic cough
High correlation found with
subjective cough
measurements [10]
Measures cough frequency
accurately
Currently limited to research
and trails
Benefit in routine clinics
is not clear
MCID: minimal clinically important difference; ERS: European Respiratory Society.
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sensory nerves. Although these results advocate the need for further investigations, thalidomide should not
be considered a routine treatment of cough in IPF, even as a second-line therapy, until further evaluation
of the benefit/risk ratio has been undertaken.
The majority of IPF patients are treated with one of the two new anti-fibrotic drugs, pirfenidone or
nintedanib [62]. Although the effect of these drugs on cough has not yet been evaluated, there are some
indications of a possible effect on cough. AZUMA et al. [63] showed, in a subgroup analysis of the phase
three trial in Japan, that pirfenidone seemed to reduce cough in patients with a forced vital capacity >70%
and arterial oxygen saturation measured by pulse oximetry <90% predicted. Using a nonvalidated cough
score, a Dutch group also observed a reduction in cough with pirfenidone use [64]. In a guinea pig model,
the capsaicin-induced cough reflex sensitivity was inhibited by pirfenidone in a dose-dependent manner
[65]. This effect was accompanied by a reduction of bronchoalveolar lavage mediators promoting cough
sensitivity [65]. No data currently exist on the effect of nintedanib on cough.
Future trials
Progress has been made in the treatment of “general” chronic cough. A combination of pregabalin and
speech therapy has been found to improve cough and QoL more than speech therapy alone [66].
Gabapentin, a neuromodulator, was shown to improve cough severity, cough frequency and QoL of
patients with chronic cough [67]. Physiotherapy aimed at suppressing cough improved sleep and cough
frequency [68]. Very recently AF-219, a P2X3 receptor antagonist, showed very promising phase two
results in chronic cough [69].
Many trials in IPF are emerging that assess the effect of these treatments or other novel medications on
cough as either a primary or exploratory end-point, illustrating the need for better cough treatment in
patients with IPF. Among these trials are studies on pirfenidone, AF-219, azithromycin, PA101, GSK2126458,
laparoscopic anti-reflux surgery, supplemental oxygen, omeprazole and cognitive behavioural therapy
(clinicaltrials.gov; searched using the terms “cough” and “IPF”; date last accessed: August 17, 2015).
Conclusion
Chronic cough in IPF is a major problem for patients and treating physicians. The pathogenesis of cough is
most likely “multifactorial” and influenced by mechanical, biochemical and neurosensory changes.
Comorbidities also have an important role, in particular GORD. While progress has been made in gaining
insight into the pathogenesis of cough in IPF, more research is needed to find effective therapies. Clinical
trials of cough treatment in IPF have only recently started, with either compounds developed for “general”
chronic cough or new compounds in development for IPF, which are also evaluated for their potential
effect on cough. It is crucial that validated cough measurements are included in these trials. Hopefully
these new studies will ultimately lead to adequate treatment of cough, thereby improving quality of life in
patients with IPF.
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